Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



From the category archives: OBN News

Product & Service Announcements

AMSBIO - Animal-Free Enzymes for In-Vitro Tissue Dissociation

AMSBIO, in association with Nordmark Biochemicals, is now offering animal-free Collagenase and Neutral Protease enzymes, isolated from Clostridium histolyticum, for in vitro tissue dissociation leading to high yields of viable cells.
 

Read the rest of entry »

AMSBIO - Cytosections for Antibody Screening and Immunohistochemistry Protocol Development

AMSBIO has launched a comprehensive range of cytosections that offer a verified, reproducible and renewable source of positive / negative controls where the expression of the target biomarker is confirmed for accuracy and specificity by an immunoassay.

Read the rest of entry »

Hayes Parsons - Intellectual Property: Insurance Overview

Intellectual Property (IP) refers to creations of the mind, such as inventions, literary and artistic works, designs and symbols, names and images. For businesses focused on innovation and the importance of their brand, protecting this IP is crucial. IP can also be infringed, if a third party disputes the use and ownership of a creation.

Read the rest of entry »

Air Products: Is it time to upgrade from aluminium storage container freezers to a larger automated freezer?

Often, research projects or sample storage facilities will start small, using just one or two containers - often referred to as ‘dewars’ - to store a few samples. As the facility grows, more and more containers are added until you have a makeshift cryo-room which probably looks something like the above image.

Read the rest of entry »

The Oxford Science Park: Immunometabolism company Sitryx expands into new space at TOSP

Sitryx, a company which is focused on regulating cell metabolism to develop disease-modifying therapeutics in inflammatory diseases and immuno-oncology, announces that it has expanded into new premises in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies.

Read the rest of entry »

The Oxford Trust: £0.5 million Headington life science laboratory development at The Oxford Trust’s Innovation Centre supported by funding secured by OxLEP

The Oxford Trust, the local charity encouraging the pursuit of science and enterprise, is to undertake a half million-pound project to install life science laboratory facilities at its Wood Centre for Innovation in Headington, Oxford, to increase capacity for the local innovation ecosystem and has received £0.1 million in funding towards the project via the Government’s Local Growth Fund, secured by the Oxfordshire Local Enterprise Partnership (OxLEP).

 

Read the rest of entry »

Milton Park: Emergex Vaccines expands at Milton Park

Emergex Vaccines, which focuses on the development of synthetic T-cell vaccines against global infectious disease threats such as COVID-19, Dengue fever, Zika, Ebola and pandemic Flu, has expanded at Milton Park in Oxfordshire, one of Europe’s largest science and technology communities.

Read the rest of entry »

AMSBIO: Breast Cancer Cell Line Array 

AMSBIO announce a new HER2 control cell line array that was developed and is proven as an effective slide quality control for HER2 expression in breast cancer tissue samples.

This new FFPE cell pellet microarray delivers a full dynamic range of HER2, ER and PR expression, validated by the Ventana system, to give immunohistochemical data in strong concordance with the routinely processed tissue sample.sections.

Read the rest of entry »

ChromoTek and Absolute Antibody Collaborate on Recombinant Engineered Antibodies

ChromoTek GmbH, part of Proteintech specializing in Nanobody-based reagents, and Absolute Antibody Ltd., a leading provider of recombinant antibody technology, today announced a partnership to offer recombinant engineered antibodies to scientists worldwide. The chimeric antibodies were originally derived from alpaca Nanobodies and engineered onto mouse and rabbit Fc domains to open up new research applications. Available antibodies target key fluorescent proteins commonly used as tags for protein visualization, as well as the structural protein vimentin.

Read the rest of entry »

AMSBIO: Mutant Spike Proteins & Antigens for SARS-CoV-2 Variant Research

AMSBIO has introduced a collection of mutated SARS-CoV-2 spike proteins and recombinant antigens for the new virus variants - B.1.1.7 and B.1.351. These reagents can be used by researchers to evaluate the efficacy of the antibodies and identify targets for development of improved therapeutic drugs and vaccines.

Read the rest of entry »

Pages: Previous1234567NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.